X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs SHASUN PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD SHASUN PHARMA ALEMBIC LTD/
SHASUN PHARMA
 
P/E (TTM) x 55.9 123.9 45.1% View Chart
P/BV x 2.3 8.5 27.4% View Chart
Dividend Yield % 0.4 0.2 187.3%  

Financials

 ALEMBIC LTD   SHASUN PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
SHASUN PHARMA
Mar-14
ALEMBIC LTD/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs7294 76.4%   
Low Rs3446 74.3%   
Sales per share (Unadj.) Rs4.7214.2 2.2%  
Earnings per share (Unadj.) Rs6.15.3 114.4%  
Cash flow per share (Unadj.) Rs6.215.8 39.5%  
Dividends per share (Unadj.) Rs0.201.00 20.0%  
Dividend yield (eoy) %0.41.4 26.4%  
Book value per share (Unadj.) Rs40.753.3 76.2%  
Shares outstanding (eoy) m267.0356.62 471.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.30.3 3,451.6%   
Avg P/E ratio x8.713.1 66.2%  
P/CF ratio (eoy) x8.54.4 191.9%  
Price / Book Value ratio x1.31.3 99.4%  
Dividend payout %3.318.7 17.5%   
Avg Mkt Cap Rs m14,1393,958 357.3%   
No. of employees `000NANA-   
Total wages/salary Rs m2072,164 9.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m1,25512,127 10.4%  
Other income Rs m370229 161.4%   
Total revenues Rs m1,62512,356 13.2%   
Gross profit Rs m1111,009 11.0%  
Depreciation Rs m38594 6.4%   
Interest Rs m2415 0.4%   
Profit before tax Rs m442230 192.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120 -404,000.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24-73 -32.9%   
Profit after tax Rs m1,630302 539.5%  
Gross profit margin %8.98.3 106.4%  
Effective tax rate %5.4-31.7 -17.1%   
Net profit margin %129.82.5 5,212.0%  
BALANCE SHEET DATA
Current assets Rs m1,8676,884 27.1%   
Current liabilities Rs m5918,456 7.0%   
Net working cap to sales %101.6-13.0 -784.4%  
Current ratio x3.20.8 387.9%  
Inventory Days Days9462 152.9%  
Debtors Days Days74108 68.4%  
Net fixed assets Rs m1,7914,970 36.0%   
Share capital Rs m534113 471.4%   
"Free" reserves Rs m10,3242,875 359.1%   
Net worth Rs m10,8583,020 359.5%   
Long term debt Rs m411,817 2.3%   
Total assets Rs m11,59113,347 86.8%  
Interest coverage x260.91.6 16,794.7%   
Debt to equity ratio x00.6 0.6%  
Sales to assets ratio x0.10.9 11.9%   
Return on assets %14.15.4 262.0%  
Return on equity %15.010.0 150.1%  
Return on capital %15.213.3 114.0%  
Exports to sales %1.546.4 3.3%   
Imports to sales %21.014.2 147.3%   
Exports (fob) Rs m195,622 0.3%   
Imports (cif) Rs m2631,728 15.2%   
Fx inflow Rs m195,843 0.3%   
Fx outflow Rs m2642,173 12.1%   
Net fx Rs m-2443,669 -6.7%   
CASH FLOW
From Operations Rs m236398 59.3%  
From Investments Rs m-224-1,635 13.7%  
From Financial Activity Rs m-271,309 -2.0%  
Net Cashflow Rs m-1571 -20.8%  

Share Holding

Indian Promoters % 64.0 39.2 163.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 3.6 5.6%  
FIIs % 9.7 17.6 55.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 39.6 65.9%  
Shareholders   54,701 20,750 263.6%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   FDC LTD.  FULFORD INDIA  CIPLA  AJANTA PHARMA  UNICHEM LAB  

Compare ALEMBIC LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY18); Net Profit Up 64.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC LTD has posted a net profit of Rs 46 m (up 64.9% YoY). Sales on the other hand came in at Rs 332 m (up 0.9% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - PANACEA BIOTECH COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS